Publications

2006

Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006;12(1):152-8.
Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, et al. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006;5(1):61-6.
Nanni S, Priolo C, Grasselli A, D'Eletto M, Merola R, Moretti F, et al. Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res. 2006;4(2):79-92.
Zhou P. REGgamma: a shortcut to destruction. Cell. 2006;124(2):256-7.
Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-, Setlur S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66(17):8337-41.
Chung KY, Morrone G, Schuringa JJ, Plasilova M, Shieh J-, Zhang Y, et al. Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation. Cancer Res. 2006;66(24):11781-91.
Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol. 2006;7(3):302-10.
Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, et al. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol. 2006;30(9):1175-83.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700